Univariate and multivariate analyses for association of recipient and/or donor statin use with various outcomes compared with control group (R−/D−, n = 464)
| Endpoint . | Univariate analysis . | Multivariate analysis . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (R+/D−, n = 16) . | (R−/D+, n = 75) . | (R+/D+, n = 12) . | (R+/D−, n = 16) . | (R−/D+, n = 75) . | (R+/D+, n = 12) . | |||||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR* (95% CI) . | P* . | HR* (95% CI) . | P* . | HR* (95% CI) . | P* . | |
| Grade 2-4 GVHD | 0.90 (0.5-1.7) | .75 | 0.89 (0.6-1.2) | .47 | 0.33 (0.1-1.0) | .06 | 1.01 (0.5-2.0) | .98 | 0.89 (0.6-1.2) | .47 | 0.33 (0.1-1.0) | .06 |
| Grade 3-4 GVHD | 2.02 (0.7-5.5) | .17 | 0.28 (0.1-0.9) | .03 | 0.00 (undefined) | .07 | 1.78 (0.6-5.0) | .28 | 0.28 (0.1-0.9) | .03 | 0.00 (undefined) | .06 |
| Chronic GVHD | 1.01 (0.5-1.9) | .98 | 0.85 (0.6-1.2) | .31 | 0.61 (0.3-1.4) | .23 | 0.93 (0.5-1.8) | .83 | 0.82 (0.6-1.2) | .26 | 0.58 (0.3-1.3) | .19 |
| Relapse/disease progression | 0.85 (0.3-2.3) | .74 | 0.66 (0.4-1.2) | .15 | 0.66 (0.2-2.7) | .57 | 0.97 (0.4-2.7) | .96 | 0.63 (0.4-1.1) | .11 | 0.74 (0.2-3.0) | .67 |
| NRM | 0.77 (0.3-2.1) | .60 | 0.86 (0.5-1.4) | .53 | 0.91 (0.3-2.8) | .86 | 0.45 (0.2-1.2) | .12 | 0.72 (0.4-1.2) | .17 | 0.66 (0.2-2.0) | .49 |
| Overall mortality | 0.80 (0.4-1.7) | .57 | 0.86 (0.6-1.2) | .42 | 0.94 (0.4-2.3) | .88 | 0.58 (0.3-1.2) | .16 | 0.73 (0.5-1.1) | .10 | 0.77 (0.3-1.9) | .56 |
| Endpoint . | Univariate analysis . | Multivariate analysis . | ||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| (R+/D−, n = 16) . | (R−/D+, n = 75) . | (R+/D+, n = 12) . | (R+/D−, n = 16) . | (R−/D+, n = 75) . | (R+/D+, n = 12) . | |||||||
| HR (95% CI) . | P . | HR (95% CI) . | P . | HR (95% CI) . | P . | HR* (95% CI) . | P* . | HR* (95% CI) . | P* . | HR* (95% CI) . | P* . | |
| Grade 2-4 GVHD | 0.90 (0.5-1.7) | .75 | 0.89 (0.6-1.2) | .47 | 0.33 (0.1-1.0) | .06 | 1.01 (0.5-2.0) | .98 | 0.89 (0.6-1.2) | .47 | 0.33 (0.1-1.0) | .06 |
| Grade 3-4 GVHD | 2.02 (0.7-5.5) | .17 | 0.28 (0.1-0.9) | .03 | 0.00 (undefined) | .07 | 1.78 (0.6-5.0) | .28 | 0.28 (0.1-0.9) | .03 | 0.00 (undefined) | .06 |
| Chronic GVHD | 1.01 (0.5-1.9) | .98 | 0.85 (0.6-1.2) | .31 | 0.61 (0.3-1.4) | .23 | 0.93 (0.5-1.8) | .83 | 0.82 (0.6-1.2) | .26 | 0.58 (0.3-1.3) | .19 |
| Relapse/disease progression | 0.85 (0.3-2.3) | .74 | 0.66 (0.4-1.2) | .15 | 0.66 (0.2-2.7) | .57 | 0.97 (0.4-2.7) | .96 | 0.63 (0.4-1.1) | .11 | 0.74 (0.2-3.0) | .67 |
| NRM | 0.77 (0.3-2.1) | .60 | 0.86 (0.5-1.4) | .53 | 0.91 (0.3-2.8) | .86 | 0.45 (0.2-1.2) | .12 | 0.72 (0.4-1.2) | .17 | 0.66 (0.2-2.0) | .49 |
| Overall mortality | 0.80 (0.4-1.7) | .57 | 0.86 (0.6-1.2) | .42 | 0.94 (0.4-2.3) | .88 | 0.58 (0.3-1.2) | .16 | 0.73 (0.5-1.1) | .10 | 0.77 (0.3-1.9) | .56 |
Adjusted for female → male sex mismatch, conditioning intensity, donor age more than 50 years, patient age more than 50 years, TAC treatment after transplantation, and disease risk.